marked.bio

brain-penetrant EGFR/HER2 inhibitor · small molecule

ORIC-114

2 active trials across 3 of our biomarkers, targeting EGFR/HER2 exon 20. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 20 insertion 2 2 Phase 1/2
EGFR exon 19 deletion / L858R 1 1 Phase 1/2
HER2 (ERBB2) activating mutation 1 1 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of ORIC-114.

  1. ORIC Pharmaceuticals 2

Trials

2 of 2 trials shown

  1. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    Recruiting Phase 1/2 ORIC Pharmaceuticals Started 2022Primary completion 2026-09 NCT05315700

    ORIC-114carboplatinpemetrexed

    …d or metastatic solid tumor with a documented EGFR or HER2 exon 20 insertion mutation or atypical EGFR mutation as determined by any nucleic acid-based diagnostic testing method, or HER2 amplification/…

    EGFR exon 19 deletion / L858REGFR exon 20 insertionHER2 (ERBB2) activating mutationSolid Tumors

  2. ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

    Recruiting Phase 1 ORIC Pharmaceuticals Started 2025Primary completion 2026-12 NCT06816992

    ORIC-114amivantamab FDA EU

    Histologically or cytologically confirmed metastatic NSCLC with a documented EGFR exon 20 insertion mutation as determined locally by any nucleic acid-based diagnostic testing method

    EGFR exon 20 insertionSolid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC